Ocular naevus and melanoma in acromegaly

Clinical Endocrinology

Volumn 47, Issue 1, 1997, Pages 119-121

  Corcuff, J B ^a   Ogor, C ^b   Kerlan, V ^b   Rougier, M B ^c   Bercovichi, M ^b   Roger, P ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; OCTREOTIDE;

ACROMEGALY; ADULT; ARTICLE; CASE REPORT; EYE CANCER; FEMALE; HUMAN; MELANOMA; NEVUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0030788613     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1997.2001010.x     Document Type: Article

References (7)

1. Barzilay, J., Heatley, G. & Cushing, G.W. (1991) Benign and malignant tumors in patients with acromegaly. Archives of Internal Medicine, 151, 1629-1632.
2. Bourguignon, J.-P., Pierard, G.E., Ernould, C., Heinrichs, C., Craen, M., Rochiccioli, P., Arrese, J.E. & Franchimont, C. (1993) Effects of human growth hormone therapy on melanocytic naevi. Lancet, 341, 1505-1506.
3. Fisher, B.J., Gaspar, L.E. & Noone, B. (1993) Radiation therapy of pituitary adenoma: delayed sequelae. Radiology, 187, 843-846.
4. Fleming, M.G., Howe, S.H. & Graf, L.H. Jr (1994) Expression of insulin-like growth factor I (IGF-I) in nevi and melanomas. American Journal of Dermatopathology, 16, 383-391.
5. Rajasoorya, C., Holdaway, M., Wrightson, P., Scott, D.J. & Ibbertson, H.K. (1994) Determinant of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95-102.
6. Ron, E., Gridley, G., Hrubec, Z., Page, W., Arora, S. & Fraumeni J.F. Jr (1991) Acromegaly and gastrointestinal cancer. Cancer, 68, 1673-1677.
7. Tavakkol, A., Elder, J.T., Griffiths, C.E.M., Cooper, D., Talwar, H., Fisher, G.J., Keane, K.M., Foltin, S.K. & Voorhees, J.J. (1992) Expression of growth hormone receptor, insulin-like growth factor I (IGH-I) and IGF-I receptors mRNA and proteins in human skin. Journal of Investigative Dermatology, 99, 343-349.